Increased Survival And Reduced Renal Injury In Mrl/Lpr Mice Treated With A Human Fc? Receptor Ii (Cd32) Peptide

Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease affecting many organs. The deposition in kidney tissue of immune complexes and their interaction with macrophages is thought to trigger the inflammatory response leading to glomerulonephritis. It has been demonstrated that inhibition of this interaction in murine models can alleviate the disease. Six synthetic peptides were derived from the membrane-proximal extracellular domain (EC2) of human Fc? receptor II (huFc?RII). Of these, one peptide, huRII6, was shown to be a potent competitive inhibitor of IgG binding to recombinant Fc?RII in vitro. To examine the possible therapeutic impact of huRII6 in vivo, this peptide, or a control, was given by subcutaneous injection to female MRL/lpr mice from weeks 7 to 36, resulting in an enhanced survival rate compared with control-treated animals and a reduction of proteinuria. Histopathological examination of the kidneys showed a reduction in deposition of immune complexes and preservation of structure. Such a functional peptide should prove useful for examining the role of IgGFc?R interactions in experimental models of disease and may provide for the development of FcR-targeting drugs to treat autoimmune disorders.